Chronic Migraine

In three clinical trials, treatment with atogepant relieved migraine symptoms as soon as day 1, with consistent reductions through 4 weeks compared with placebo, according to research published in Neurology.

SAN DIEGO — Obtaining serum vitamin levels in children with migraine should be part of symptom management, particularly for older adolescents, according to a speaker at the American Headache Society Annual Scientific Meeting.

SAN DIEGO — Distinctions between burdens faced by those who experience different levels of chronic and episodic migraine should be drawn according to external health care-related factors rather than by symptoms alone, according to a poster.

DENVER — For those experiencing chronic migraine, the presence of self-reported psychiatric conditions did not affect the effectiveness of eptinezumab, according to a poster at the American Academy of Neurology annual meeting.

Treatment with atogepant 60mg once daily significantly reduced monthly migraine days at 12 weeks compared with oral rimegepant 75mg every other day, according to research published in Cephalalgia.

Last week, Healio provided live coverage of the American Headache Society Annual Meeting in Austin, Texas, where health care professionals gathered for the latest updates on headache disorders.

AUSTIN, Texas — Long-term use of eptinezumab resulted in improvements in symptoms and headache days in patients with chronic migraine and medication-overuse headache, according to a poster presented here.

AUSTIN, Texas — Atogepant significantly improved daily functioning and reduced physical impairment in adults with chronic migraine within 1 week of treatment, according to study results presented here by Jessica Ailani, MD.

AUSTIN, Texas — In-clinic administration of IV ketamine significantly improved refractory chronic migraine pain intensity in a small cohort of patients, according to a poster presented here.

The FDA has approved expanding the indication of Qulipta, an oral calcitonin gene-related peptide receptor antagonist, for preventing migraine in adults.